Patient Frequently Asked Questions (FAQs)

Patient FAQs

Adamas is developing ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD) and for the treatment of patients with multiple sclerosis (MS) who have impaired walking.


Is ADS-5102 available to help me?

ADS-5102 is an experimental medicine and is not approved by the U.S. Food and Drug Administration (FDA).

How can I participate in a clinical trial?

Adamas is not currently enrolling patients in clinical trials. Please check back for future updates.

About Adamas

Dedicated to developing new medicines to improve the daily lives of those affected by chronic neurologic disorders. Learn more